Telomeres and cardiovascular diseases: Facts, controversies and limitations

Andres, V; Dorado, B; Spyridopoulos, I

doi:10.1201/9781315371382

Telomeres and cardiovascular diseases: Facts, controversies and limitations

Lookup NU author(s): Professor Ioakim Spyridopoulos ORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2017 by Taylor & Francis Group, LLC. Despite advances in diagnosis and treatment, CVD remains the major cause of morbidity and mortality in industrialized countries and is expected to become so worldwide by 2020. The economic, social and human costs associated with CVD treatment are immense. To improve diagnosis, prevention and treatment, it is thus urgent to refine classic CVD risk scores and identify new genetic, cellular and molecular mechanisms underlying disease initiation and early progression. This chapter examines advances in our understanding of the role of telomere shortening in the etiopathogenesis of CVD, and discusses limitations and perspectives for future research.